142 related articles for article (PubMed ID: 17705017)
1. Metastasis of the gastrointestinal tract: FDG-PET imaging.
Hayasaka K; Nihashi T; Matsuura T; Yagi T; Nakashima K; Kawabata Y; Ito K; Katoh T; Sakata K; Harada A
Ann Nucl Med; 2007 Aug; 21(6):361-5. PubMed ID: 17705017
[TBL] [Abstract][Full Text] [Related]
2. [Evaluation of FDG-PET imaging for the detection of gastrointestinal tract cancer in patients with suspected lung cancer].
Uesaka D; Demura Y; Umeda Y; Morikawa M; Nakanishi M; Kadowaki M; Mizuno S; Ameshima S; Miyamori I; Sasaki M; Ishizaki T
Nihon Kokyuki Gakkai Zasshi; 2006 Dec; 44(12):899-905. PubMed ID: 17233385
[TBL] [Abstract][Full Text] [Related]
3. Role of 18F-fluorodeoxyglucose positron emission tomography in detecting extrahepatic metastasis in pretreatment staging of hepatocellular carcinoma.
Yoon KT; Kim JK; Kim DY; Ahn SH; Lee JD; Yun M; Rha SY; Chon CY; Han KH
Oncology; 2007; 72 Suppl 1():104-10. PubMed ID: 18087190
[TBL] [Abstract][Full Text] [Related]
4. Gastrointestinal malignancies evaluated with (18)F-fluoro-2-deoxyglucose positron emission tomography.
Chin BB; Chang PP
Best Pract Res Clin Gastroenterol; 2006 Feb; 20(1):3-21. PubMed ID: 16473798
[TBL] [Abstract][Full Text] [Related]
5. Pulmonary lymphangitic carcinomatosis (PLC): spectrum of FDG-PET findings.
Acikgoz G; Kim SM; Houseni M; Cermik TF; Intenzo CM; Alavi A
Clin Nucl Med; 2006 Nov; 31(11):673-8. PubMed ID: 17053382
[TBL] [Abstract][Full Text] [Related]
6. Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diophosphate bone scan to detect bone metastases in patients with non-small cell lung cancer.
Hsia TC; Shen YY; Yen RF; Kao CH; Changlai SP
Neoplasma; 2002; 49(4):267-71. PubMed ID: 12382027
[TBL] [Abstract][Full Text] [Related]
7. [The role of positron emission tomography in the detection of incidental gastrointestinal tract lesions in patients examined for lung cancer].
Isobe K; Hata Y; Sakaguchi S; Takai Y; Shibuya K; Takagi K; Homma S
Nihon Kokyuki Gakkai Zasshi; 2010 Jul; 48(7):482-7. PubMed ID: 20684209
[TBL] [Abstract][Full Text] [Related]
8. Whole-body 18F-FDG PET in recurrent or metastatic nasopharyngeal carcinoma.
Yen RF; Hong RL; Tzen KY; Pan MH; Chen TH
J Nucl Med; 2005 May; 46(5):770-4. PubMed ID: 15872349
[TBL] [Abstract][Full Text] [Related]
9. The impact of 18F-FDG PET/CT on assessment of nasopharyngeal carcinoma at diagnosis.
King AD; Ma BB; Yau YY; Zee B; Leung SF; Wong JK; Kam MK; Ahuja AT; Chan AT
Br J Radiol; 2008 Apr; 81(964):291-8. PubMed ID: 18344274
[TBL] [Abstract][Full Text] [Related]
10. Positron emission tomography and bone metastases.
Fogelman I; Cook G; Israel O; Van der Wall H
Semin Nucl Med; 2005 Apr; 35(2):135-42. PubMed ID: 15765376
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of FDG-PET/CT in the detection of pancreatic metastases from lung cancer.
Sato M; Okumura T; Kaito K; Kiyoshima M; Asato Y; Uchiumi K; Iijima H; Hashimoto I; Kaburagi T; Amemiya R
Ann Nucl Med; 2009 Jan; 23(1):49-57. PubMed ID: 19205838
[TBL] [Abstract][Full Text] [Related]
12. Nasopharyngeal carcinoma staging by (18)F-fluorodeoxyglucose positron emission tomography.
Chang JT; Chan SC; Yen TC; Liao CT; Lin CY; Lin KJ; Chen IH; Wang HM; Chang YC; Chen TM; Kang CJ; Ng SH
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):501-7. PubMed ID: 15890593
[TBL] [Abstract][Full Text] [Related]
13. [[18F]-FDG-PET in the diagnostics of gastrointestinal tumors].
Buchmann I; Ganten TM; Haberkorn U
Z Gastroenterol; 2008 Apr; 46(4):367-75. PubMed ID: 18393156
[TBL] [Abstract][Full Text] [Related]
14. In-111 DTPA-octreotide scintigraphy for disease detection in metastatic thyroid cancer: comparison with F-18 FDG positron emission tomography and extensive conventional radiographic imaging.
Sarlis NJ; Gourgiotis L; Guthrie LC; Galen B; Skarulis MC; Shawker TH; Patronas NJ; Reynolds JC
Clin Nucl Med; 2003 Mar; 28(3):208-17. PubMed ID: 12592128
[TBL] [Abstract][Full Text] [Related]
15. [18F]5-fluoro-2-deoxyuridine-PET for imaging of malignant tumors and for measuring tissue proliferation.
Buchmann I; Vogg AT; Glatting G; Schultheiss S; Möller P; Leithäuser F; Schulte M; Gfrörer W; Kotzerke J; Reske SN
Cancer Biother Radiopharm; 2003 Jun; 18(3):327-37. PubMed ID: 12954120
[TBL] [Abstract][Full Text] [Related]
16. The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions.
Lan XL; Zhang YX; Wu ZJ; Jia Q; Wei H; Gao ZR
Clin Radiol; 2008 Jul; 63(7):756-64. PubMed ID: 18555033
[TBL] [Abstract][Full Text] [Related]
17. Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases.
Kao CH; Hsieh JF; Tsai SC; Ho YJ; Yen RF
Anticancer Res; 2000; 20(3B):2189-92. PubMed ID: 10928175
[TBL] [Abstract][Full Text] [Related]
18. [The application of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer].
Xu HF; Liu Y; Zhang JH; Zhou RS; Zhou FH; Yuan MH
Zhonghua Jie He He Hu Xi Za Zhi; 2005 Feb; 28(2):108-11. PubMed ID: 15854393
[TBL] [Abstract][Full Text] [Related]
19. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan.
Chung JK; So Y; Lee JS; Choi CW; Lim SM; Lee DS; Hong SW; Youn YK; Lee MC; Cho BY
J Nucl Med; 1999 Jun; 40(6):986-92. PubMed ID: 10452315
[TBL] [Abstract][Full Text] [Related]
20. Comparison of 18F-FDG PET and bone scintigraphy in detection of bone metastases of thyroid cancer.
Ito S; Kato K; Ikeda M; Iwano S; Makino N; Tadokoro M; Abe S; Nakano S; Nishino M; Ishigaki T; Naganawa S
J Nucl Med; 2007 Jun; 48(6):889-95. PubMed ID: 17504877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
